Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes

verfasst von: Chang Chunkang, Yang Rui, Xu Feng, Guo Juan, Zhang Xi, Wu Lingyun, Li Xiao, Wang Jianmin

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

We performed flow cytometric analysis of CD34+ cell apoptosis in 22 patients with myelodysplastic syndrome (MDS) and 7 patients with de novo acute myeloid leukemia (AML) using annexin V-FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in low-grade MDS group (IPSS score ≤ 1.0) compared with high-grade MDS group (21.33 vs. 7.27%, P < 0.001) and patients with de novo AML (21.33 vs. 7.53%, P < 0.001). There was no correlation between apoptosis and patient’s age or gender. Our results confirmed that CD34+ cell apoptosis was significantly increased in low-grade MDS, which was featured as bone marrow failure. CXCR4 protein expression on CD34+ cell surface in the low-grade MDS was lower than high-grade MDS (10.42 vs. 16.97, P = 0.014) and AML group (10.42 vs. 20.26, P < 0.001). But there was no statistical significance between low-grade MDS and the control group (P = 0.496). Furthermore, we measured SDF-1 levels in BM plasma from patients by enzyme-linked immunosorbent assay (ELISA), and no difference was found. We found a negative correlation between apoptosis and CXCR4 expression. Our data indicate that CXCR4 might be the prognostic marker of MDS.
Literatur
1.
Zurück zum Zitat Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:543–57.PubMed Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:543–57.PubMed
2.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed
3.
Zurück zum Zitat Galili N, Cerny J, Raza A. Current treatment options: impact of cytogenetics on the course of myelodysplasia. Curr Treat Option Oncol. 2007;82:117–28.CrossRef Galili N, Cerny J, Raza A. Current treatment options: impact of cytogenetics on the course of myelodysplasia. Curr Treat Option Oncol. 2007;82:117–28.CrossRef
4.
Zurück zum Zitat Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–8.PubMedCrossRef Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–8.PubMedCrossRef
5.
Zurück zum Zitat Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMed Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMed
6.
Zurück zum Zitat Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118–29.PubMedCrossRef Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118–29.PubMedCrossRef
7.
Zurück zum Zitat Tiu R, Gondek L, O’Keefe C, et al. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia. 2007;21:1648–57.PubMedCrossRef Tiu R, Gondek L, O’Keefe C, et al. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia. 2007;21:1648–57.PubMedCrossRef
8.
Zurück zum Zitat Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111–20.PubMedCrossRef Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111–20.PubMedCrossRef
9.
Zurück zum Zitat Broxmeyer HE, Cooper S, Kohli L, et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol. 2003;170:421–9.PubMed Broxmeyer HE, Cooper S, Kohli L, et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol. 2003;170:421–9.PubMed
10.
Zurück zum Zitat Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–5.PubMed Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–5.PubMed
11.
Zurück zum Zitat Parker JE, Fishlock KL, Mijovic A, et al. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075–82.PubMedCrossRef Parker JE, Fishlock KL, Mijovic A, et al. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075–82.PubMedCrossRef
12.
Zurück zum Zitat Parker JaneE, Mufti GhulamJ, Feyrooz Rasool. The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932–8.PubMed Parker JaneE, Mufti GhulamJ, Feyrooz Rasool. The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932–8.PubMed
13.
Zurück zum Zitat Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedCrossRef Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedCrossRef
14.
Zurück zum Zitat Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–33.PubMedCrossRef Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–33.PubMedCrossRef
15.
Zurück zum Zitat Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-lineadapted HIV-1. Nature. 1996;382:833–5.PubMedCrossRef Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-lineadapted HIV-1. Nature. 1996;382:833–5.PubMedCrossRef
16.
Zurück zum Zitat Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91:2305–9.PubMedCrossRef Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91:2305–9.PubMedCrossRef
17.
Zurück zum Zitat Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G proteincoupled receptor. Science. 1996;272:872–7.PubMedCrossRef Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G proteincoupled receptor. Science. 1996;272:872–7.PubMedCrossRef
18.
Zurück zum Zitat Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591–4.PubMedCrossRef Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591–4.PubMedCrossRef
19.
Zurück zum Zitat Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595–9.PubMedCrossRef Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595–9.PubMedCrossRef
20.
Zurück zum Zitat Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95:9448–53.PubMedCrossRef Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95:9448–53.PubMedCrossRef
21.
Zurück zum Zitat Spoo AnkeC, Lübbert Michael, William G, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786–91.PubMedCrossRef Spoo AnkeC, Lübbert Michael, William G, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786–91.PubMedCrossRef
22.
Zurück zum Zitat Matsuda M, Morita Y, Hanamoto H, et al. CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia. 2004;18:1038–40.PubMedCrossRef Matsuda M, Morita Y, Hanamoto H, et al. CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia. 2004;18:1038–40.PubMedCrossRef
23.
Zurück zum Zitat Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359:716–22.PubMedCrossRef Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359:716–22.PubMedCrossRef
24.
Zurück zum Zitat Fuhler GM, Drayer AL, Vellenga E. Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. Blood. 2003;101:1172–80.PubMedCrossRef Fuhler GM, Drayer AL, Vellenga E. Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. Blood. 2003;101:1172–80.PubMedCrossRef
25.
Zurück zum Zitat Fuhler GM, Drayer AL, Olthof SG, et al. Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell-derived factor-1 induced migration of CD34+cells from patients with myelodysplasia. Blood. 2008;111:359–68.PubMedCrossRef Fuhler GM, Drayer AL, Olthof SG, et al. Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell-derived factor-1 induced migration of CD34+cells from patients with myelodysplasia. Blood. 2008;111:359–68.PubMedCrossRef
Metadaten
Titel
The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes
verfasst von
Chang Chunkang
Yang Rui
Xu Feng
Guo Juan
Zhang Xi
Wu Lingyun
Li Xiao
Wang Jianmin
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9678-x

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.